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Acute myeloid leukemia (AML) is characterized by relapse and treatment resistance in a major 
fraction of patients, underlining the need of innovative AML targeting therapies. Here we analysed 
the therapeutic potential of an innovative biohybrid consisting of the tumor-associated peptide 
somatostatin and the photosensitizer ruthenium in AML cell lines and primary AML patient samples. 
Selective toxicity was analyzed by using CD34 enriched cord blood cells as control. Treatment of OCI 
AML3, HL60 and THP1 resulted in a 92, and 99 and 97% decrease in clonogenic growth compared to the 
controls. Primary AML cells demonstrated a major response with a 74 to 99% reduction in clonogenicity 
in 5 of 6 patient samples. In contrast, treatment of CD34+ cB cells resulted in substantially less 
reduction in colony numbers. Subcellular localization assays of RU-SST in OCI-AML3 cells confirmed 
strong co-localization of RU-SSt in the lysosomes compared to the other cellular organelles. our data 
demonstrate that conjugation of a Ruthenium complex with somatostatin is efficiently eradicating 
LSc candidates of patients with AML. this indicates that receptor mediated lysosomal accumulation of 
photodynamic metal complexes is a highly attractive approach for targeting AML cells.
Acute myeloid leukemia (AML) is initiated and propagated by cancer stem cells. Although these leukemic stem 
cells (LSCs) initially respond to chemotherapy, most patients relapse and die from the disease1. One explanation 
is that current therapies only eliminate the tumor bulk which lacks leukemic stem cell properties whereas the 
LSCs are relatively insensitive. Growing knowledge of the molecular landscape of AML has led to clinical testing 
of new drugs against driver mutations as well as antibody-based therapies against cell surface proteins with partly 
disappointing results2–5. Thus, for the majority of patients there is therapeutic standstill and the urgent need for 
innovative treatment approaches. Tumor-associated peptides provide attractive characteristics for AML-targeted 
strategies such as easy availability, convenient purification and storage. In addition, they are less immunogenic, 
have a high tissue penetration and a high affinity to cellular biomarkers. They provide a rapid clearance from 
the body and are excellent candidates for straight forward conjugation strategies. It has been shown that soma-
tostatin receptors (SSTR) are expressed on leukemias such as T-cell leukemia and AML6,7. Using a somatosta-
tin radiobinding assay it was demonstrated that around 12.5% of AML cases express somatostatin receptors6. 
Previously, it has been shown that primary AML progenitor cells, characterized by the co-expression of CD34 
and CD117 express the somatostatin receptor (SSTR) subtype 2 and that the expression of the SSTR2 receptor 
was not restricted to the immature CD34+CD117+ compartment, but also detected on more differentiated AML 
blasts. Using a transwell migration assay, it was demonstrated that the migration of AML cells towards a gradient 
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of the synthetic analogue of somatostatin octreotide, correlated with the expression of SSTR28. indicating that 
somatostatin might influence spreading of AML cells8. Based on these findings, somatostatin receptors might be 
a potential interesting target for the treatment of AML. In the current approach we analysed the AML targeting 
potential of an innovative biohybrid consisting of the tumor-associated peptide somatostatin and the photosen-
sitizer ruthenium using molecularly and cytogenetically fully annotated primary AML patient samples as targets.
Our own previous results using lung cancer cell lines demonstrated that this new biohybrid is highly selec-
tive and potent: cellular uptake is mediated by clathrin-dependent endocytosis and followed by efficient gener-
ation of singlet oxygen upon irradiation with negligible dark toxicity.9. These results were now translated into a 
pre-clinical setting mimicking the potential application of such a construct in the context of ex vivo purging of 
autologous bone marrow (BM) transplants in AML.
Materials and Methods
cell culture, AML cell lines and primary samples. Quantitiative real-time PCR analyses of the expres-
sion of SSTR2 as well as functional testing of the RU-SST compound were performed on the following leukemic 
cell lines: OCI-AML3 (OA3), THP-1, HL60, MonoMac6 (MM6), K562, KASUMI, MV4-11, Nalm6, NB4 (all 
DSMZ, Braunschweig, Germany). Cells were cultured in RPMI 1640 medium with 10% FBS (K562, HL60, THP1, 
Nalm6, MV4-11, and MM6) or 20% FBS (OCI-AML3) supplemented with 1% penicillin-streptomycin.
Mononuclear cells were isolated from bone marrow (BM) or peripheral blood (PB) from patients with pri-
mary diagnosed AML, analyzed for their SSTR2 expression (n = 13) and cultured with the RU-SST bioconjugate 
to test the toxicity of the compound (n = 6). All patient samples were investigated by cytomorphological, cytoge-
netic and molecular analyses after written informed consent as described10. Diagnosis was made according to 
the French-American-British criteria and the World Health Organization classification (Table 1)11,12. The study 
was approved by the ethic committee of the University of Ulm. in accordance with the ethical principles of the 
declaration of Helsinki (http://www.wma.net/en/30publications/10policies/b3/index.html). Leukemic cells were 
thawed and kept in culture with culture conditions as mentioned previously13.
Cells from cord blood (CB) were enriched for CD34+ using the human CD34 Micro Bead Kit ultrapure 
(Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer instructions.
Annexin V staining. Apoptosis was measured by Annexin V staining using the Annexin V apoptosis detec-
tion kit (BD Biosciences 2350 Qume Drive, San Jose, CA 95131). Experiments were performed according to the 
manufacturer’s protocol. In brief, OCI-AML3, MM6 and THP-1 cells were incubated with RU-SST as described 
in the Materials and Methods part. Subsequently, cells were washed and incubated with 7-AAD and Annexin V 
for 15 min. at room temperature. Samples stained with Annexin V or 7-AAD alone were taken as controls. The 
analysis was performed on a FortessaTM flow cytometer (Becton Dickinson, CA, USA).
cfc assay. To evaluate the toxicity of the bioconjugate on clonogenic progenitor cells, AML cell lines as well 
primary human cells were incubated with the compound for 4 hours. Subsequently, cells were washed and cell 
counts were determined via trypan blue exclusion. Colony forming cell unit (CFC) assays were performed as 
described previously14. In all cases cell numbers placed in methylcellulose were calculated according to the initial 
cell number at the start of the experiment, not taking into account any cell loss during the incubation time. 1000 
cells (OCI-AML3 and HL60) and 500 cells (THP1) were plated per dish (methocult H4330). For primary patient 
samples, 10,000 cells were plated per dish in methylcellulose H4330 (Stem Cell Technologies, Vancouver, BC, 
Canada) and supplemented with cytokines. For the CD34+ enriched CB cells, 300 cells were plated per dish in 
methocult H4434 (Stem Cell Technologies, Vancouver, BC, Canada). Each experiment was performed in dupli-
cates and values mentioned are Mean ± SEM.
Patient no. Gender Age (years) Karyotype Other relevant markers
1 F 33 46XX[20] NPM1 mut
2 F 61 46XX[13] NPM1 mut
3 F 75 46,XX [20] None
4 M 72 47,XY [14] None
5 F 63 46,XX[20] NPM1 mut






8 F 87 47,XX, + 13[9]46,XX[11] FLT3-TKD
9 M 23 46,XY[20] FLT3-ITD
10 F 43 46XX[23] NPM1 mut,FLT3-ITD
11 M 60 47,XY + 8[20] None
12 F 43 46,XX[20] NPM1 mut, FLT3-ITD
13 F 41 n.e. FLT3-ITD
Table 1. Patients’ characteristics of samples incubated with RU-SST and RU-Alkyne.
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Determination of reactive oxygen species. OCI-AML3 and CD34+ CB cells were placed on Retronectin 
(r-fibronectin) (Takara; CH-296 cat#T100A) overnight. CD34+ CB were kept in culture in IMDM medium contain-
ing BIT (Stem Cell Technologies, Vancouver, BC, Canada) and supplemented with a cytokine cocktail containing 
100 ng/mL Flt-3 ligand, 100 ng/mL steel factor, 20 ng/mL interleukin-3, 20 ng/mL IL-6, and 20 ng/mL granulocyte 
colony-stimulating factor (G-CSF) as described previously15. Cells were washed gently with PBS and incubated with 
fresh medium containing RU-SST for 4 hours in duplicates. Subsequently, cells were washed again and half of the 
cells was either exposed for 6 minutes to light or kept in the dark (Dark control)9. Cells were washed twice with PBS. 
Pre-warmed staining solution containing Cellular Reactive Oxygen Species Detection Assay Kit was added (Deep Red 
Fluorescence) (Abcam, Cambridge, UK). The cells were incubated for 30 min at 37 °C. After staining cells were carefully 
washed and replaced with HyCloneTM DMEM medium (VWR, Darmstadt, Germany) and proceeded for observation 
under a confocal microscope or for flow cytometric analysis. The live cell imaging was performed using a LSM 710 
laser scanning confocal microscope system (Zeiss, Germany) coupled to an XL-LSM 710 S incubator and equipped 
with a 63x oil immersion objective. The acquired images were processed with ZEN 2011 software (Zeiss, Oberkochen, 
Germany)9. The corrected total cell fluorescence (CTCF) was calculated as previously described16–18 using the ImageJ 
v1.5 software (NIH, USA).
For flow cytometric analysis of ROS cells were further treated with propidium iodide in order to determine 
dead cells and analyzed on a FACS FortessaTM (Becton Dickinson). PI negative (alive) cells were gated and ana-
lyzed for the expression of ROS.
Statistical analyses. Statistical analysis was performed using the Mann-Whitney test for independent sam-
ples. Flow cytometry data were analyzed with FlowJo™ (Becton Dickinson). Differences with p values less than 
0.05 were considered to be statistically significant (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Values 
mentioned are Mean ± SEM. GraphPad PRISM® 6 (Version 06.01; La Jolla, California, USA) was used for the 
analyses and figures. Correlation coefficients were calculated using Microsoft Excel 2010.
Results
expression of somatostatin receptors in cytogenetic subgroups of AML compared to normal 
progenitor cells. To investigate the potential role of somatostatin receptors as targets for anti-leukemic ther-
apy, we analyzed AML cell lines representing various cytogenetic subgroups for the expression of somatostatin 
receptors by qRT-PCR. SSTR2 expression was detected in all cell lines tested, with the highest expression in 
THP-1 (Supplemental Fig. 1). In addition, we analyzed published data using RNA-Seq19 (GSE49642) from 43 
primary AML patient samples. We observed that SSTR2 and to a lesser extent SSTR3 were expressed in a part of 
AML patient samples (Supplemental Fig. 2A). Those patient samples which showed the highest expression had a 
normal karyotype together with a mutation of the nucleophosmin 1 gene19. SSTR2 expression was also present in 
other subtypes of AML as demonstrated in the microarray analysis of various AML data sets including the TCGA 
and MILE data (Supplemental Fig. 2B). In contrast, SSTR2 was not or only low expressed in HSC and dimly 
expressed in MPP, BC and CMP depending on the probe set (Supplemental Fig. 2B). To evaluate whether SSTRs 
would also be expressed on normal early hematopoietic progenitor cells, we further examined published RNASeq 
data from sorted subpopulations from CB20. Among all somatostatin receptors it was SSTR2 which was expressed 
mainly in the megakaryocyte erythroid progenitor cells and seemed to be significantly lower expressed especially 
on the most primitive HSC population (Supplemental Fig. 2C). RNA sequencing experiments showed similar 
results with a high expression of SSTR2 in CD34 positive hematopoietic stem cells as well as proerythroblasts21 
(Supplemental Fig. 2D).
Stability of the RU-SSt bioconjugate. The ruthenium complex (RU) and the peptide hormone soma-
tostatin (SST) were conjugated as described previously in order to combine the LSC selectivity of somatostatin 
with the potent photosensitizer ruthenium utilizing CLICK chemistry approaches9. A lysine residue is located 
within the SST receptor binding domain. Therefore, non-specific lysine modifications are not applicable for the 
conjugation of SST. However, N-terminal modification could be applied via solid phase synthesis to maintain the 
binding properties of the SST9.
The stability of RU-SST was analyzed by liquid mass spectrometry (LC-MS) using similar culture conditions 
as in the cell culture experiments. The LC-MS study showed that the amount of RU-SST present in 10% fetal calf 
serum (FCS) in PBS remains consistent up to 8 h. Furthermore, there was no additional peak observed in the 
liquid chromatogram at 254 nm, which would indicate peptide fragmentation (Supplemental Fig. 3A–C). Taken 
together, these data indicated that RU-SST is stable up to 8 h in FCS.
Uptake and efficiency of RU-SST. To demonstrate the superior cellular uptake and efficiency of RU-SST 
within leukemic cells we chose the OCI-AML 3 and HL60 cell lines. OCI-AML3 (OA3) cells were incubated 
with RU-SST or the unconjugated RU-Alkyne control for 4 hours and analyzed using laser scanning confocal 
microscopy9. SSTR2 expression was confirmed by RT-PCR and western blot (data not shown). Uptake studies 
were performed in OA3 using a laser excitation at 458 nm which corresponds to the Metal to Ligand Charge 
Transfer (MLCT) absorbance of the Ruthenium metal complex. Emission images ranging from 580–707 nm were 
recorded9. We could clearly observe a high uptake of RU-SST in OA3 cells with an average integrated intensity of 
40302 A.U./cell (range 111030-3932 A.U./cell), demonstrating that the biohybrid RU-SST was transported ade-
quately into the cells. There was a significantly higher emission intensity inside the cells compared to the con-
trol experiment using the unconjugated RU-Alkyne (average integrated intensity of 12898 A.U./cell, p < 0.0001, 
Mann-Whitney test) (Fig. 1A–C).
To determine the effective concentration of RU-SST and to compare it with the unconjugated control, HL60 
cells were incubated with increasing concentrations of the compound and RU-Alkyne, respectively, for 4 hrs 
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in the dark and subsequently exposed to light. RU-SST was highly toxic to HL60 cells with an IC50 value of 
47.4 ± 3 µM after light irradiation (Fig. 1D). The IC50 was not reached with up to 100 µM for RU-SST or the 
model complex in the dark. RU-SST displayed a phototoxicity index (PI) of >2.1 (PI is obtained by dividing dark 
and light IC50 values). RU-SST (IC50 = 47.4 ± 3 µM) was also more effective when compared to the unconjugated 
RU-Alkyne complex (IC50 > 100 µM), pointing to a superior cellular uptake and thereby leading to a greater 
potential of RU-SST for photodynamic therapy (PDT). Cellular uptake of RU-SST could be blocked upon addi-
tion of an SSTR 2 specific antibody further verifying ligand mediated SST functionalization (Fig. 1D).
RU-SST effectively impairs AML growth. To measure the effect of RU-SST on leukemic clonogenic pro-
genitor cells we placed cell lines and primary patient samples in methylcellulose assays.
We could detect a significant decrease in colony growth in the OCI AML3 cell line with a 92% reduction of 
colony growth when the cells were incubated with RU-SST and exposed to light compared to the cells treated with 
RU-SST and not exposed to light (Fig. 2A). Interestingly, the incubation of the cells with RU-SST and without 
light exposure did not cause a significant reduction in colony growth when compared to an untreated control. 
Furthermore, there was no comparable reduction in colony growth when the cells were treated with the uncon-
jugated RU-Alkyne control and exposed or not exposed to light. A similar response to RU-SST with exposure 
to light was also observed in the HL60 and THP1 cell lines with a 99% and 97.66% reduction of colony growth 
respectively, compared to the RU-SST dark control (Fig. 2B) (p < 0.002; Mann-Whitney test). Treatment of these 
cell lines with increasing concentrations of the somatostatin analogue octreotide did not affect cell proliferation 
(Supplemental Fig. 4). Toxicity of the compound was due to the induction of apoptosis as demonstrated for the 
THP1, Mono Mac 6 and HL60 cell lines (Supplemental Fig. 5).
To test the efficacy in primary AML samples, we chose patient samples from which we could previously 
demonstrate that they were able to form colonies in methylcellulose assays, representing a small subset of AML 
genotypes (data not shown). Quantitative expression analysis demonstrated that these patients (n = 6) showed 
a variable expression of SSTR2 receptors (Supplemental Fig. 6). After treatment, CFC counts demonstrated an 
average reduction of colony numbers of 89.5% (±4.0% SEM) in 5 out of 6 samples and 44.79% reduction in 1 out 
of 6 samples analysed at day 14 in comparison to samples treated but not exposed to light (Dark RU-SST).). In 
contrast, the unconjugated control (RU-Alkyne) did not show a significant reduction in CFC numbers with an 
average reduction of 17.6 (±7.03 SEM) (dark Ru-Alkyne) and 31.4 (±8.97% SEM) RU-Alkyne with exposure to 
light, respectively (Table 2).
Uptake and toxicity in cord blood cells. To evaluate, whether the effect of the compound was selective 
for AML stem and progenitor cells, we analysed the toxicity of the compound for CD34+ enriched CB cells 
(n = 6). Uptake studies were performed for both conjugates prior to proceeding to the experiments. We could 
observe a high uptake of RU-SST in CB cells with an average integrated intensity of 35521.14 ± 5541 SEM A.U./
cell (range 59221 to 12184 A.U./cell), demonstrating that the biohybrid RU-SST was transported efficiently into 
the CB cells despite lower SSTR2 expression on HSCs. The emission intensity inside the cells was significantly 
Figure 1. Uptake and IC50 studies of RU complex: confocal images of OCI-AML3 cells incubated with RU-
SST (50 μm) (A) and RU-Alkyne control (RU-Alk) (100μm) (B) for 4 hrs. The laser intensity was measured for 
alexaflour (430 nm). Uptake characteristics with values of the integrated intensity (a.u.) per cell (C). Bar graphs 
indicate the average integrated intensity per cell in both experimental arms. Cells analysed for RU-SST (n = 45) 
and RU-Alk (n = 44). Data are represented as mean ± SEM. (D) IC50 was calculated in HL60 AML cell lines. 
Percent cell survival was measured by trypan blue exclusion after 4 h incubation with RU-Alk (control), RU-SST 
(irradiated) compared to RU-SST in the absence of light (dark RU). Experiments performed for dark RU-SST 
(n = 6); RU-Alk (n = 3), for RU-SST (n = 3). Data are represented as mean ± SEM.
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higher compared to the control experiment using the unconjugated RU-Alkyne (average integrated intensity 
of 3409.25 ± 366.2 SEM A.U./cell, p < 0.0001, Mann-Whitney test) (Supplemental Fig. 7A,B). To test the toxic-
ity of the compound on colony growth, we treated CB cells with RU-SST and the unconjugated RU-Alkyne as 
described. We observed a mean reduction of 25.4% (±6.82 SEM%) in colony numbers when the CB cells were 
treated with RU-SST and exposed to light with an average colony number of 140.6 CFC per 300 input cells (±37.9 
SEM) compared to 173.2 colonies per 300 input cells in the dark control (±31.3 SEM) (Fig. 3A). The unconju-
gated RU-Alkyne only showed a minor toxicity on normal CB cells with a reduction of 18.59% (±4.88% SEM) in 
colony numbers compared to dark RU-SST (Fig. 3B). These data point to a superior toxicity of RU-SST on AML 
samples compared to healthy CD34+ stem cell candidates (Fig. 3C).
Lysosomal localization and generation of reactive oxygen. To evaluate, whether the differ-
ential toxicity of RU-SST was due to a different uptake or subcellular localization we used different subcel-
lular organelle dyes and laser scanning confocal microscopy. In OCI-AML3 cells, there was a clear and very 
strong co-localization of RU-SST in the lysosomes (Pearson’s coefficient 0.94, Fig. 4A, strong to moderate 
co-localization in membranes (Pearson’s coefficient 0.70, Fig. 4B) and mitochondria (Pearson’s coefficient 0.60, 
Fig. 4C), and a poor co-localization in the nucleus (Pearson’s coefficient 0.35, Fig. 4D). In comparison, CD34+ 
CB cells showed almost no significant uptake of the bioconjugate in the same cellular compartments tested 
(Supplemental Fig. 8A–D), suggesting that the lysosomes and mitochondria may be the intracellular targets 
for photodynamic killing of leukemic cells mediated by RU-SST in AML cells. Experiments measuring ROS 
generation demonstrated that intracellular localization of RU-SST induced high levels of ROS in OCI-AML3 
cells after exposure to light compared to the treated dark control cells (Fig. 5A,B,D) as well as to the RU-Alkyne 
control (Fig. 5C). Flow cytometric analysis of reactive oxygen species (ROS) in primary AML samples (n = 3) 
demonstrated a significant higher production of ROS in primary AML cells compared to CD34 positive CB cells. 
In detail, the mean fluorescence intensity was 5.7 (±1.19 SEM) fold higher in the RU-SST arm compared to the 
RU-SST dark control and 7.4 (±2.9 SEM) higher when compared to the RU-SST treated CD34+ CB control cells 
(p < 0.05) (Fig. 5E,F). These data indicate that the differential generation of reactive oxygen species induced by 
RU-SST in primary AML samples versus the CB progenitor cells is responsible for the pronounced toxicity of 
the compound in patient samples.
Figure 2. Determination of clonogenic potential of AML cell lines with RU-complexes: (A) Bar graph shows 
the number of colonies after day 14 of plating cells on methylcellulose in OCI-AML3 AML cells. Significance 
was calculated using the Mann-Whitney test (** < 0.01). (B) Percent reduction in the number of colonies 
compared to dark control in OCI-AML3, HL60 and THP-1 AML cells. The bars represent mean ± SEM (n = 3).
CFC/104 cells (% reduction)
control 6 min RU-SST Dark RU-Alk 6 min RU-Alk
AML#1 100 26 (74) 153 (0) 78 (22)
AML#2 252 139 (44.7) 247 (2.0) 208 (17.7)
AML#3 137 1 (99.2) 187 (0) 211 (0)
AML#4 47 5 (89.3) 29 (38.2) 24 (48.9)
AML#5 118 4 (96.6) 72 (38.9) 69 (41.5)
AML#6 70 8 (88.5) 36(48.5) 29 (58.7)
Table 2. Toxicity of Ru-SST on clonogenic progenitor cells. *control = dark RU-SST.
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Discussion
Chemotherapy treatment of patients with newly diagnosed AML consists of a remission induction followed by 
a post-remission therapy (PRT). Remission induction is applied to reduce the leukemic cell burden in a patient 
below the level of morphological detectability. Post-remission therapy is needed because 70–80% of patients who 
initially respond to the induction therapy ultimately relapse and die without subsequent additional treatment due 
to persistent minimal residual disease1.
Autologous hematopoietic cell transplantation (auto-HSCT) is one option for a post-remission therapy: previ-
ous studies could show its beneficial effect in patients with good risk cytogenetics22,23. Superior outcome has been 
demonstrated in patients with CBF24 NPM mutated25 and CEBPA double mutated (CEBPA dm)26 AML. Potential 
disadvantages of auto-HSCT consists of the lack of a graft versus leukemia effect and a contamination of the graft 
with leukemic stem and progenitor cells, which might contribute to relapse27.
Purging strategies have been developed and tested over the last decades using physical systems, cytotoxic 
therapies, immunological in vitro and in vivo techniques, molecular and genetic methods ex vivo cultivation as 
well as cytokine mediated activation of immune effector cells with varying success28–32.
Limitations of these strategies were toxicity on normal hematopoietic stem cells, lack of expression of targets 
on leukemic stem cells, requirement of long exposure time with subsequent loss of engrafting capacity and a sub-
sequent delay in hematopoietic recovery resulting in a higher morbidity and mortality.
In the current approach, we analysed the AML targeting potential of an innovative biohybrid consisting of the 
tumor-associated peptide somatostatin and the photosensitizer ruthenium using molecularly and cytogenetically 
fully annotated primary AML patient samples. As ASCT is one treatment option for AML patients, photody-
namic therapy (PDT) might be a beneficial approach to eliminate contaminating AML cells from an autologous 
graft. Furthermore, it might help to separate and examine AML cells by taking advantage of the tumor-localizing 
properties for fluorescence diagnosis and fluorescence activated cell sorting.
In a first step, we analysed the expression of somatostatin receptors 1–5 on leukemic cells from AML cell 
lines and primary AML patient samples. Mainly, SSTR2 was expressed in various myeloid leukemic cell lines as 
well as on leukemic cells of patients with AML. In contrast, expression of SSTR2 was negligible on HSCs from 
healthy donors, indicating that SSTR2 might be a potential target for therapy. Somatostatin-receptor-targeted 
anti-cancer therapy has been developed by conjugating various chemotherapeutic agents or radionuclides to 
SSTR2-preferential somatostatin analogues33. However, conjugation, synthesis and purification set significant 
limitations. In this study, we used a biohybrid consisting of somatostatin conjugated to the potent photosensitizer 
Ruthenium. Ruthenium(II) complexes are attractive candidates for PDT as they provide favourable features such 
photophysical properties, easy synthesis, flexible physical properties (i.e. charge, lipophilic properties or redox 
potential by coordination of the appropriate ligands), low sensitivity of photochemical properties to pH-value 
variations34,35. In addition, they are characterized by low side effects on healthy tissues, when tested in vivo in 
mouse models36. Therefore, ruthenium(II) complexes and their bioconjugates are particularly attractive for tar-
geted PDT.
Treatment of OCI-AML3, HL60 and THP-1 with this biohybrid resulted in a 92%, 97.5% and 99% decrease in 
CFCs compared to the controls. Primary AML cells from patients with AML at diagnosis demonstrated a major 
response with a 74–99% reduction in CFCs in 5 of 6 and a minor response with a 45% reduction in CFCs in 1 of 
4 patient samples. In contrast, treatment of CD34+ CB cells resulted in a substantially lower reduction in CFCs.
Subcellular localization assays of RU-SST in OCI-AML3 cells confirmed the clear co-localization of RU-SST 
in the lysosomes (Pearson’s coefficient 0.94) compared to a moderate to low localization in other cellular sub 
compartments like mitochondria and nucleus. Lysosomes are critically involved in fundamental processes such 
Figure 3. Effect of RU-complexes on clonogenicity of normal CD34+ cells: cells from four CD34+ enriched 
cord blood (CB) samples (n = 6) were tested for the effect of both RUSST and RU-Alkyne compounds. The 
bar graphs represent the average colony numbers of each experimental arm performed in duplicates. Percent 
reduction was determined based on the colony numbers generated from CB cells treated with RU-SST and 
exposed to light compared to dark RU-SST. C) Bar graphs show the percent decrease in CFC growth of AML 
samples compared to normal CB CD34+ cells. Significance calculated by Mann-Whitney test ** < 0.01.
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Figure 4. Evaluation of localization of the RU complexes: (A–D): (A) Confocal microscopy images of OCI-
AML3 cells incubated with RU-SST (Panel 1) and RU-Alkyne (Panel 2) and treated with organelle trackers for 
(A) lysosomes, (B) mitochondria, (C) membrane and (D) nuclei. The panels of each figure show (a) RU-SST 
emission, (b) corresponding bright field images, (c) emission from the organelle trackers, and (d) overlay of all 
three images.
Figure 5. Determination of reactive oxygen species (ROS) levels (A,C) Confocal microscopy images of OCI-
AML3 cells incubated with RU-SST (A) and RU-Alkyne (C) and treated with ROS reporter and kept in the 
dark (Panel 1) or exposed to light (Panel 2). (a) ROS reporter, (b) corresponding bright field image, (c) overlay. 
(B) Bar graph indicates the fluorescence intensity corresponding to A) for untreated OCI-AML3 cells, after 
treatment with RU-SST in the dark as well as after exposure to light (irradiatíon). Significance calculated by 
Mann-Whitney test *** < 0.001 and * < 0.05. (D) Bar gaph indicates the fold CTCF (The corrected total cell 
fluorescence) of ROS reporter before and after irradiation compared to untreated cells. (E) Bar graph indicated 
the Mean fluorescence intensity (MFI) of ROS measurement in primary AML (n = 3) and nCB-CD34+ (n = 3) 
cells. (F) Bar graph indicates the fold increase of MFI after irradiation with RU-SST compared to Dark control 
in primary AML samples and were compared to the fold reduction in nCB-CD34+ cells (n = 3). Significance 
was calculated by 2way ANOVA with *p < 0.05, **p < 0.01.
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as protein secretion, endocytic receptor recycling, energy metabolism, autophagy and cell signaling37. It has been 
demonstrated that a variety of cancers use the autophagy–lysosome pathway in order to avoid cell death, immune 
surveillance, and deregulating metabolism38. Based on this, targeting of lysosomes promises to substantially 
impair cancer growth. Furthermore, cancer cells use lysosomes to degrade cancer drugs in an acidic environ-
ment37. Lysosomal targeting has been shown to be successful in leukemic stem cells through increased ROS 
production39. Targeting lysosomal enzymes can eradicate imatinib resistant CML40. Furthermore, it was shown, 
that the size of the lysosomes is significantly larger in AML stem and progenitor cells as compared to their healthy 
controls and that targeting of lysosomes in AML patient samples might be an attractive and novel approach for 
an anti-leukemic therapy39. Our data show that the conjugation of a Ruthenium complex with somatostatin could 
be highly attractive to eradicate leukemic cells of patients with AML. The lysosomal localization along with SSTR 
receptor mediated approach might be beneficial as it imposes a potential apoptosis route via subcellular and/or 
cellular targeting strategy keeping the healthy cells intact.
Analysing the effect of RU-SST on the generation of reactive oxygen species (ROS) revealed a 7.4-fold increase 
in ROS levels in primary AML cells compared to normal CD34+ cells by flow cytometry indicating that the 
ROS generation is one of the key mechanisms for the apoptosis mediated cell death in AML cells induced by 
RU-SST. Induction of reactive oxygen species (ROS) has been shown to be a major mechanism of anti-cancer 
drugs: this has been shown also in AML at the level of LSCs, with reducing LSC load but sparing normal HSCs. 
ROS induction has been described for ABT-737 and ABT-263, both Bcl-2 inhibitors41, Parthenolide (PTL)42 and 
dimethylaminoparthenolide (DMAPT)43, the vitamin A derivative Fenritinide44, Niclosamide45, Celastrol and 
4-hydroxy-2-nonenal (HNE)46,47, 3-deazaneplanocin A (DZNep) and Mefloquin48.
To the end, it has to be emphasized that the effect of RU-SST might vary in different AML subtypes and that 
only a small subset of AML subtypes were tested in this study. However, in the current analysis the induction of 
reactive oxygen species by RU-SST after exposure to light together with its subcellular localization point to an 
effective mechanism to treat AML progenitor cells in a variety of AML genotypes.
Data availability
No datasets were generated or analysed during the current study.
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